Research graph
References from Effectiveness, treatment pattern, and safety of ustekinumab in treating bio-naïve patients with Crohn’s disease in the real-world clinical setting in China. Local targets link to admitted publications; unresolved targets remain external evidence.
ECCO guidelines on therapeutics in Crohn’s disease: Medical treatment
10.1093/ecco-jcc/jjz180 · 2020 · External reference
Efficacy of ustekinumab for inducing endoscopic healing in patients with Crohn’s disease
10.1053/j.gastro.2018.06.035 · 2018 · External reference
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn’s disease: A multicentre, randomised, double-blind, parallel-group, phase 3b trial
10.1016/s0140-6736(22)00688-2 · 2022 · External reference
Real-world effectiveness and safety of ustekinumab in bio-naive patients with moderate-to-severe Crohn’s disease: A Canadian multi-center study
2023 · External reference
Clinical, endoscopic, and radiological effectiveness of ustekinumab in bio-naive versus bio-experienced patients with Crohn’s disease: Real-world experience from a large Canadian center
10.1093/ibd/izac149 · 2023 · External reference
